Quaker Chemical Expects To Close Houghton Combination In Q4 2018

Quaker Chemical Corp. (KWR) said it continues to be in productive discussions with the European Commission and Federal Trade Commission regarding its combination with Houghton International Inc.

Based on these discussions, Quaker continues to expect the remedy will involve a divestment of some product lines which, in total, are approximately 3 percent or less of the revenues of the combined company. Quaker noted that this is consistent with its original projections and previous comments.

Quaker is in talks with potential buyers for the product lines to be divested and intends to present a remedy that meets the needs of both regulatory authorities in the third quarter.

Based on the information available to date, Quaker said it expects to receive approval from the regulatory authorities and close the combination with Houghton in the fourth quarter of 2018.

Michael Barry, Chairman, Chief Executive Officer and President of Quaker said, "While the regulatory process is taking longer than expected, it is moving in the right direction with constructive discussions with both regulatory authorities. The additional time will allow us to finalize the process with the potential buyers and the regulators."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT